In the heart of the historic city of Versailles, a 15-minute walk from the magnificent Château de Versailles, lies Kanna Sucre. This exceptional establishment is not just another CBD store, it is a harmonious blend of well-being and tranquility, offering an unrivaled experience.

Passion for quality

Kanna Sucre’s passion lies in bringing the best CBD products to market, and this passion is born from a deep commitment to the well-being of its customers, employees and the local community. This commitment is the driving force behind the creation of their premium products.

At Kanna Sucre, you are not just a customer, you are a guest in tea lover’s paradise. This charming boutique offers a unique experience akin to a traditional tea room. Discover their selection of delicious CBD-infused teas, infusions and treats, which you can enjoy on site. Whether you enjoy a cup of Japanese Genmaïcha tea or indulge in their homemade milk chocolate, Kanna Sucre promises you an unforgettable experience that nourishes both body and mind.

Its extensive product line ranges from vaping hardware and e-liquids to cosmetics, flowers, resin and oils. Quality is of paramount importance here, with much of their offering being certified organic, demonstrating their commitment to your wellbeing.

Create an oasis of serenity

Entering Kanna Sucre is like entering an oasis of tranquility in the heart of the bustle of Versailles. This carefully curated space is designed not only as a boutique, but also as a sanctuary where you can relax and immerse yourself in the world of CBD. With comfortable Chesterfield-style armchairs, intimate private lounges and a calming atmosphere, Kanna Sucre invites you to explore the benefits of CBD at your own pace.

Kanna Sucre firmly believes that well-being is a fundamental right. CBD is at the forefront of their offering, and their tea room introduces you to an array of flavors from original teas, floral infusions and, of course, CBD-infused creations that excite the taste buds. Savor exceptional tea, indulge in delicious pastries and don’t forget to try their homemade milk chocolate, all designed to elevate your senses and promote relaxation.

Kanna Sugar

59, Avenue de Saint-Cloud
78000 Versailles
Tuesday to Saturday 1 p.m. – 8:30 p.m.
0970929520

Home Kanna-Sucre

The plan to legalize cannabis in Germany will be on the agenda of the Bundestag on Friday October 13, 2023.

The CDU/CSU group, which opposes legalization, will also table its motion entitled “Stop the legalization of cannabis, improve health protection – strengthen education, prevention and research”. It will be discussed during a 40-minute debate.

Both motions will then be referred to the parliamentary health committee for further consideration.

At the end of last month, the CDU/CSU motions failed in the Bundesrat.

The coalition parties have already indicated that they want to significantly expand and improve the bill, including by adding ediblesallowing social functions within Cannabis Clubs and reducing penalties for possession, among other things.

Legalization of cannabis in Germany: the bill

The proposed bill aims to legalize cannabis, a previously illegal substance, for personal use under certain conditions.

The proposal maintains the restriction of legal possession and consumption of cannabis to adults. It would also allow private possession and cultivation of cannabis plants for non-commercial communities.

The German government says this bill will contribute to a more responsible use of cannabis and improve health protection.

The new regulations in detail

Under the proposed bill, adults will in future be allowed to possess up to 25 grams of cannabis for personal use and cultivate up to three cannabis plants privately. Cannabis plants cultivated privately must, however, be protected against access by children and adolescents.

Non-commercial cultivation associations – Cannabis Clubs – will also be allowed to supply cannabis to their members for their personal use, subject to strict rules. For example, the maximum number of members of these associations is set at 500 people, who must have their residence in Germany. Only one membership in a cultural association is authorized. Distribution of cannabis to members is limited to a maximum of 25 grams per day or 50 grams per month.

Cannabis consumption is prohibited within a 200 meter radius around Cannabis Clubs, schools, nurseries, playgrounds and public sports facilities.

There is also a general ban on advertising and sponsorship of Cannabis Clubs.

The German government has already launched an information campaign. The impact of this change in law on society will be evaluated after four years. Medical cannabis regulations remain unchanged.

A new monograph of the Cannabis flower was recently adopted at a session of the European Pharmacopoeia Commission held in June.

A monograph of this type is used to provide guidance on the basic specifications of an herbal medicine. This is the first modern official monograph of Cannabis in a widely adopted pharmacopoeia.

The cannabis flower monograph is now available online and will be published in Supplement 11.5 of the European Pharmacopoeia (Ph. Eur.) in January 2024. It includes information such as the appropriate way to collect and process a sample of dried cannabis flower, and is intended for use with the General Monograph on Herbal Medicines, which also includes requirements that may be relevant.

The European Directorate for the Quality of Medicines and Healthcare (EDQM) plans to organize a webinar for its members on December 14, 2023, to present the new monograph. The implementation of the text is then planned for July 1, 2024.

The organization says the new monograph takes into account information received from several national authorities regarding the use of cannabis in their jurisdictions and includes additional limits for arsenic, cadmium and lead in cases where the medicinal plant must be prescribed to patients.

What impact for medical cannabis in Europe?

The new monograph will be important for companies that produce cannabis in Europe, with new standards to meet, and for companies that export cannabis to the European market. It will provide clearer criteria for the classification of different cannabis chemotypes and establish specific tests/requirements for identification, foreign material content, loss on drying, heavy metals and cannabinoid content.

“The importance and influence of the European Pharmacopoeia in the Canadian and global cannabis industry cannot be overstated. The inclusion of a monograph dedicated to cannabis consolidates the growing acceptance of this plant and provides necessary clarity to cannabis producers in Canada and around the world,” explains Tom Ulanowski, Chairman of the C-45 Board of Directors. Quality Association, an industry association that represents QAPs, labs and others in Canada’s cannabis industry, at StratCann.

He also adds that cannabis analysis laboratories will have to integrate these changes when they come into force next summer.

“Canadian cannabis producers generally use the American or European pharmacopoeia to release batches of cannabis flowers, both for domestic and international markets. This new monograph will require companies to update their batch release and testing criteria by July 2024. Analytical laboratories may also need to expand the scope of their testing services to ensure that they are able to meet the requirements of the new monograph. »

“The impact of this monograph is considerable. Not only will it shape the European and Canadian markets, but it is also poised to influence the trajectory of the U.S. Pharmacopoeia, which has yet to publish its own cannabis-specific monograph. »

The United States Pharmacopeia (USP) also recently proposed a new monograph for cannabis.

“As part of the safety net that protects and promotes public health in the United States, USP is taking steps to prevent harm to patients from exposure to substandard, over-potent, contaminated, or adulterated cannabis intended for medical use under state law,” the authors of the new USP monograph wrote earlier this year.

A true reference in the CBD industry since 2017, the WEED SIDE STORY site is recognized both for its superior quality products and for its unparalleled expertise in the field of cannabidiol.

Carefully selected suppliers

We have chosen to work exclusively with renowned producers and suppliers, thus guaranteeing pure and natural products. Thanks to our rigorous selection process, we offer you products of excellent quality. Each item available on our site meets the strictest standards in production and safety.

“Since its debut in 2017, Weed Side Story has become a major player in the CBD industry. Our passion for quality, our dedication to our customers and our constant desire to improve have made us an essential reference.

Clean production

From the beginning, we chose to also become CBD producers ourselves, growing our own plants to guarantee impeccable quality to our customers. From seed selection to harvesting, including CBD extraction: each stage of production is carefully controlled.

You will find a wide range of CBD products in our catalog: flowers, resins, oils, e-liquids, shisha products, infusions, not forgetting the accessories!

Inform you and support you

At Weed Side Story, we believe in the importance of knowledge because we are aware that purchasing CBD products can sometimes raise questions. This is why our blog is a real mine of information with detailed articles, user guides and practical advice. We help you understand the benefits of CBD and choose the right products for your needs. Don’t hesitate to take a look!

Attractive prices

We are proud to offer you an exceptional selection of CBD products at unbeatable prices. With us, quality does not rhyme with exorbitant prices. We firmly believe that access to high-quality CBD products should be affordable for everyone, and that is why we strive to maintain competitive pricing without compromising on the excellence of our products. Plus, every Wednesday, don’t miss our special promotions that make our prices even more irresistible.

After six months of deliberations, the Citizens’ Assembly on Drug Use has completed its review of the issues, having heard from a wide range of experts on all aspects of drug use.

The panel’s final sessions took place on Sunday, October 1, and the 99 members are expected to meet again later this month to agree on their recommendations. A final report will then be submitted to the Oireachtas, the Irish parliament, by the end of the year.

Members have now heard 180 hours of collective discussion from experts in fields including health, politics, academia and frontline services, as well as from individuals, families and communities who have been affected by drug use.

Assembly Speaker Paul Reid told the Irish Times that there is a “strong desire for change” and a feeling among members that criminalization is “harsh”.

The Citizens’ Assembly, established in Ireland in 2016, examines various political issues every 18 months. A report is then produced on each subject, to which the Irish government is required to respond.

The form decriminalization will take remains to be seen

The exact form that this “desire for change” will take remains to be determined.

The Crainn Group, which specializes in drug policy and education, spoke to the Citizens’ Assembly in September, specifically on the arguments for decriminalizing cannabis possession, home cultivation and the implementation of a Cannabis Social Club model.

A representative for Crainn, Ryan McHale, told Cannabis Health that he hoped these measures would be included within the scope of the Assembly’s recommendations, but was concerned that members would opt for a diversion system that would force all drug users into compulsory treatment instead of being incriminated.

“We would support this approach for more ‘problematic’ and more harmful drugs, such as heroin or crack, but it would be impossible and inhumane to include cannabis in this approach.”

Eamon Keenan, who represents the Irish health service, confirmed at one of the meetings that the measure would include non-problem drug users if implemented, “which we totally disagree with”.

Lack of discussions on legalization

Drug reform advocates have expressed disappointment in the lack of commentary on the effects of full legalization and regulated market models. Mr Reid told the Irish Times he “did not get the impression that members were going to legalize some or all drugs” – although there were “extreme views” on both sides.

“While we are disappointed that legalization is not included in the final recommendations, as reported in the Irish Times, this is not at all surprising,” McHale continues.

“Members of the Assembly have received virtually no working documents on legalization, and especially no representatives of other countries that have legalized have been invited to share their expertise. »

The omission of medical cannabis

There was also no discussion about medical cannabis and the major challenges that remain when it comes to patient access.

Ireland has been criticized for its “restrictive” medical cannabis policy. The medical cannabis access program (Medical Cannabis Access Program, MCAP) was launched in 2019, but access is limited to people meeting one of three requirements.

To date, fewer than 100 patients have been able to access cannabis-based medicines through this program, with many traveling abroad to legally access cannabis.

“It is disappointing that medical cannabis has also not been given a thorough review, despite it being a major issue for many people in Ireland,” added Mr. McHale.

“There should have been more emphasis on the issues affecting cannabis users of all stripes, including oral testimony from a number of patients who have fled Ireland or are consuming on the illicit market. »

What is happening now?

The recommendations are just that – recommendations – and it will then be up to policymakers to follow them and decide whether they should be implemented in the country’s drug laws. However, citizens’ assemblies have already had significant leverage in enabling constitutional changes on a number of key issues.

The format grew out of the 2012-2014 Constitution Convention which considered a wide range of constitutional issues identified for discussion. Following this convention, the government held the Marriage Equality Referendum in May 2015, which introduced same-sex marriage.

The model was then applied to a series of citizen assemblies covering a wide range of issues, including abortion, culminating in the referendum on repeal of the Eighth Amendment in 2018.

Speaking after the meeting on Sunday 1 October, Mr Reid said the Citizens’ Assembly represented the most comprehensive assessment and review of drugs policy in Ireland, and he added that members were well equipped to approve final recommendations in the coming weeks.

“Over the next three weeks, members will receive draft recommendations that reflect the nature of the conversations held to date. They will have the opportunity to further discuss these draft recommendations to ensure that they reflect the nature of these discussions. Members will then vote on these recommendations at the next meeting at the end of the month,” he commented.

“This is a thorough process. All sides of the debate, many different points of view and local, national and international perspectives were shared. Members now have the opportunity to speak and I would like to thank them for their work and dedication in reaching a conclusion that will result in change. »

In September 2024, Bilbao will welcome enthusiasts and professionals of the sector during a special edition of Spannabis, thus consolidating Spain’s position as a key epicenter of the European cannabis industry.

Europe’s main cannabis fair will also be held in Barcelona in March (15th to 17th) as usual.

A new chapter: Spannabis Bilbao

The Feria del Cáñamo, which welcomes more than 70,000 participants, has ambitious plans for 2024. In addition to the already traditional Barcelona event in March, Spannabis Bilbao will be inaugurated in September, with the hope of replicating the same success in the Basque capital.

After the interruption in 2023 of Expogrow, the last major cannabis event in the Basque Country, Spannabis seized the opportunity to fill the void.

The organizers chose Bilbao for several reasons, including the presence of a growing cannabis community and a culture open to consumption. In addition, Bilbao, with its high gross domestic product, offers optimal infrastructure for major events. The city is also an icon of architectural design.

Spannabis Bilbao will be held at the Bilbao Exhibition Centre, covering 10,000m² of indoor space and an additional 2,000m² outdoors for stages and catering areas. The event will take place on September 20, 21 and 22, 2024.

In addition to stands and exhibitors, attendees will be able to access expert talks and learn about new developments in the sector. Tickets are available online and at the exhibition center ticket offices.

An area will be exclusively dedicated to hemp and CBD, where participants can learn about the benefits of these natural products from experts.

As a preamble to the Bilbao event, Spannabis Barcelona, ​​which serves as an inspiration and model, has everything planned for its March 2024 edition. With 280 international exhibitors and the presence of World Cannabis Conferences in its 12th edition, it promises to once again be a benchmark event. Furthermore, the Spannabis Champions Cup will judge the traditional categories of cannabis products.

The Regional Administrative Court (TAR) of Lazio suspended the decree which included oral preparations of CBD in the table of narcotics.

This suspension follows an initiative by ICI (Imprenditori Canapa Italia), who filed an appeal with the Lazio Regional Administrative Court on October 3, with the help of the law firm Prestige Legal & Advisory.

The preventive suspension of the CBD decree was made possible by the fact that, after the entry into force of the decree, the sector witnessed indiscriminate seizures in several stores, even of products – such as flowers or cosmetic products – which had nothing to do with what was indicated in the decree.

“In order to avoid serious and irreparable damage to the entire sector, through Decree No. 6652/2023 published on 5.10.2023, Tar Lazio granted the request for suspension of the DM of 7.8. 2023 formulated by ICI”, explained the president of ICI, Raffaele Desiante, to our colleagues from DolceVitaOnline, adding that the motivation is as follows: “Considering that, taking into account what was deduced on this point in the appeal as well that from the attached documentation which proves the seizure and closure of the companies, it is considered that the conditions are met for the granting of the request for monocratic precaution requested in accordance with article 56 of the Code of Civil Procedure, pending the collegial treatment “.

As a result of the aforementioned decree, the ministerial decree classifying oral CBD preparations as a narcotic is suspended until the council chamber scheduled for October 24.

Last February 14, Tar Lazio confirmed the legality of the use of the apical parts of the plant, therefore hemp flowers, on the basis of Italian law (242 of 2016) and European and international regulations.

“The suspension is justified, even in light of what has happened since its entry into force, with indiscriminate seizures of everything, flowers, oils and products, without distinction,” emphasizes lawyer Giacomo Bulleri. This is certainly confirmation that it is an anti-scientific measure, because it did not make sense to include it in the table of narcotics when it could be considered a medicine, and secondly anti-legal, given that EU rules must be respected. An alignment process is underway in Europe, so going backwards does not contribute to market stability.”

A hemp strain genetically engineered to produce little or no THC has been approved by the U.S. Department of Agriculture (USDA) as safe to grow and reproduce on U.S. soil.

The USDA’s Animal and Plant Health Inspection Service (APHIS) issued an advisory last week regarding these plants, created and submitted by the company Growing Together Research, an Indiana-based biotechnology company specializing in cannabis, hemp, psychedelics and agriculture. APHIS regulates the “movement of genetically engineered or modified organisms.”

“APHIS found that this modified hemp is unlikely to present an increased risk of plant pests compared to other cultivated hemp,” the USDA advisory states. “Therefore, it is not subject to 7 CFR part 340. From a pest risk perspective, this hemp can be cultivated and bred safely in the United States. »

Growing Together Research announced in June this year that it had succeeded in modulating the amount of delta-9-THC expressed in plants. They explained that their experiment was intended to help American hemp farmers whose crops sometimes exceed the limit of 0.3% THC due to environmental conditions, a threshold at which the law requires that all of the harvest is destroyed.

GTR’s announcement also hinted at ongoing experiments to try to get Cannabis plants to produce more THC than normal.

“Based on its demonstrated ability to reduce or turn off genes coding for THC expression, GTR is now applying the same techniques to increase THC expression. GTR will soon begin collaborating with academic and commercial partners based in Canada to create a cannabis cultivar with increased THC expression. A first round of high-THC cultivars is expected to be created by the third quarter of 2023,” GTR said in June.

According to GTR, nearly 10% of American hemp crops had to be destroyed between 2018 and 2020 due to too high a delta-9-THC level.

“Understanding the mechanisms of the THC pathway is perhaps the most important element to truly unlocking the promise of cannabis and hemp,” said Sam Proctor, CEO of GTR. “We are very excited about the results achieved to date and look forward to continuing to innovate for the benefit of stakeholders in the cannabis and hemp supply chain.” »

The latest developments suggest that Barbados is closer than ever to launching its domestic medical cannabis industry. The Barbados Cannabis Authority announced last July a new partnership with the tech company GrowerIQ, which will manage the monitoring and reporting of all cannabis production on the island.

This partnership aims to “set cutting-edge standards” not only for the island’s thriving medical cannabis industry, but also for the region as a whole.

A spokesperson for the Barbados Medicinal Cannabis Licensing Authority (BMCLA) then declared to Business of Cannabis : “The BMCLA intends to continue to develop policies and guidelines that should create an environment for the industry to create high-quality, targeted medical cannabis products made with distinctive Bajan flavor and excellent value added, and which can establish themselves in the international market as a reflection of a creative vision of Barbados and of great value to this country. »

Cannabis in Barbados

Barbados, like its neighboring Caribbean islands, has a long history with cannabis, so it has always been in high demand.

This history has led to particularly strict rules regarding the possession and cultivation of cannabis. Until recently, anyone accused of possession for personal use could be fined up to US$112,000 or face up to five years in prison, while those found in possession of more than 15 grams could be accused of “trafficking” and risk a sentence of up to life in prison.

However, in 2019, the Barbadian government, under the leadership of Prime Minister Mia Mottley, passed the Medical Cannabis Industry Act, with regulations to follow in 2020.

The BMCLA explained that, in an effort to ensure “the rollout was as inclusive as possible”, the Joint Select Committee requested presentations from the public on their expectations for the medical cannabis industry.

A “cannabis” unit, under the Ministry of Agriculture, Food Safety and Nutrition, was also created in 2019 to facilitate the deployment of the medical cannabis industry, with a team responsible for studying and ‘examine best practices from around the world, including those of regional partners like Jamaica and Saint Vincent and the Grenadines, which have already opened up their cannabis industries.

“Once this groundwork was completed and the legislation passed after extensive consultation, the BMCLA opened its doors to the public on January 18, 2021.”

In December 2020, in the midst of the Coronavirus pandemic, which had significantly impacted the island’s economy, the Minister of Agriculture and Food Safety, Indar Weir, declared: “The industry must start… (The advantages economics are) something we cannot ignore. We must take advantage of our position now. »

In September 2020, a referendum was held, which saw the decriminalization of possession of up to 14 grams of cannabis, with those caught in the act being fined $200 in the form of a ‘penalty notice’. fixed”, similar to a traffic ticket.

A vision for the future

After just under two years of existence, the BMCLA has approved nine licensees, for a total of 18 licenses.

Barbados’ licensing structure includes eight distinct categories with varying levels, covering everything from micro-cultivators to importers, exporters, laboratories and retail distributors.

This latter category allows licensees to establish a “therapeutic establishment”, a place where one can receive a prescription for medicinal cannabis from a pharmacist and consume it on site under the care and attention of the pharmacist. health professionals.

“This allows for the development of spa-style medical tourism, where the establishment can be located on a beach or in the beautiful Barbados countryside, where one can also enjoy the atmosphere,” explained the health organization. regulation.

Additionally, licenses are granted for a period of five years, inclusive of all fees, allowing licensees “not only to start their business, but also to have the opportunity to grow without having to worry about annual renewal fees.”

With the foundations laid for the island’s businesses to thrive, the new partnership with BMCLA marks the start of the next phase, during which the body will focus on ensuring quality products and “transparency so to ensure regulatory compliance while safeguarding patient well-being.”